ClinicalTrials.gg
CompletedNCT01557166Updated Nov 1, 2017Results posted

Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea

A Phase 3 interventional study of liraglutide and placebo in Metabolism and Nutrition Disorder, Obesity and Obstructive Sleep Apnoea, sponsored by Novo Nordisk A/S. Completed at 42 sites in 2 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2017-11-01.

Primary conditionObesityRegistry: Nutrition DisordersReclassifiedWhy we changed it
Registry
Nutrition Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Nutrition Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
359
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 79 studies testing liraglutide in Obesity — 7 open to participants now, 9 under way, 2 of them phase 3. Liraglutide · Obesity.

Enrollment
9th of 79
359 · median 70
Started
2012
with 1 other
Phase 3
17 of 79
1 open now
Registered
7th of 79
by date
Lead sponsor
16 of 79
Novo Nordisk A/S

Among the 79 studies testing liraglutide in Obesity, this one is the 9th largest by enrollment, is one of 2 that started in 2012, is one of 17 in phase 3, and was the 7th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

7 of the 79 studies testing liraglutide in Obesity are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies testing liraglutide in Obesity, or all of them as a file.
02

Study summary

This trial is conducted in North America. The aim of the trial is to investigate the effect of liraglutide in obese subjects with sleep apnoea.

03

Conditions studied

  • Metabolism and Nutrition Disorder
  • Obesity
  • Obstructive Sleep Apnoea

Browse trials for

Keywords

  • OSA
04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 359 is above the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nutrition Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • equal to or above 30 kg/m\^2
  • Stable body weight (less than 5% self-reported change during the previous 3 months)
  • Diagnosis of moderate or severe obstructive sleep apnoea (OSA)
  • Unwilling or unable to use continuous positive airway pressure (CPAP) (or other positive airway pressure) treatment. No CPAP (or other positive airway pressure) treatment for at least four weeks prior to screening
  • Ability and willingness to comply with all protocol procedures e.g. correct handling of trial product, compliance to visit schedule and dietary advice and complete trial related questionnaires

Exclusion criteria

Exclusion Criteria:

  • Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 inhibitors or insulin within the last 3 months prior to screening
  • Diagnosis of type 1 or type 2 diabetes per judgement of the investigator
  • Glycosylated () equal to or above 6.5%
  • Significant craniofacial abnormalities that may cause OSA
  • Respiratory and neuromuscular diseases that could interfere with the results of the trial in the opinion of the investigator
  • Use of central stimulants, hypnotics, mirtazepine, opioids, trazodone within the previous 3 months prior to screening
  • Obesity induced by drug treatment
  • Treatment with pramlintide, sibutramine, orlistat, zonisamide, topiramate or phenteremine within the last 3 month prior to screening
  • Previous surgical treatment for obesity
  • Screening calcitonin equal to or above 50 ng/L
  • Familial or personal history of Multiple Endocrine Neoplasia type 2 or familial Medullary Thyroid Carcinoma
  • Personal history of non-familial Medullary Thyroid Carcinoma
  • History of chronic pancreatitis or idiopathic acute pancreatitis
  • History of Major Depressive Disorder or suicide attempts
  • Systolic blood pressure equal to or above 160 mmHg and/or diastolic blood pressure equal to or above 100 mmHg
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
359 participants (actual)

Study arms

  • Experimental
    Liraglutide 3.0 mg

    Drug: liraglutide

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • 3.0 mg liraglutide administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise

  • Drugplacebo

    Placebo administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise

07

What researchers measure

Primary outcomes

  1. Change From Baseline in Apnoea-hypopnoea Index (AHI)

    Observed mean change from baseline in AHI (events/hour) after 32 weeks of treatment. AHI (apnoea and hypopnoea events per hour of sleep) is a measure used for the diagnosis and severity classification of obstructive sleep apnoea. AHI severity category: none ≤4.9; mild 5.0-14.9; moderate 15.0-29.9; severe ≥30.0 events/hour.

    Time frame: Week 0, Week 32

Secondary outcomes

  1. Change From Baseline in Body Weight (kg)

    Observed mean change from baseline in fasting body weight (kg) after 32 weeks of treatment.

    Time frame: Week 0, week 32

  2. Change From Baseline in Fasting Plasma Glucose

    Observed mean change from baseline in fasting plasma glucose (mmol/L) after 32 weeks of treatment.

    Time frame: Week 0, week 32

  3. Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%)

    Observed mean change from baseline in glycosylated haemoglobin (HbA1c) (%) after 32 weeks of treatment.

    Time frame: Week 0, week 32

08

Results

Posted Feb 9, 2015

Participant flow

The trial was conducted at 40 sites in 2 countries, as follows: United States: 35 sites; Canada: 5 sites.

Participant flow — Overall Study
MilestoneLiraglutide 3.0 mgPlacebo
Started180179
Exposed176179
Completed134142
Not completed4637
Withdrew: Adverse event206
Withdrew: Lack of efficacy21
Withdrew: Protocol violation85
Withdrew: Withdrawn consent1220
Withdrew: Target dose not tolerated10
Withdrew: Psychiatric disorder10
Withdrew: Unclassified25

Outcome measures

PrimaryChange From Baseline in Apnoea-hypopnoea Index (AHI)

Observed mean change from baseline in AHI (events/hour) after 32 weeks of treatment. AHI (apnoea and hypopnoea events per hour of sleep) is a measure used for the diagnosis and severity classification of obstructive sleep apnoea. AHI severity category: none ≤4.9; mild 5.0-14.9; moderate 15.0-29.9; severe ≥30.0 events/hour.

Time frame:
Week 0, Week 32
Reported as:
Mean · events/hour
Change From Baseline in Apnoea-hypopnoea Index (AHI)
events/hourLiraglutide 3.0 mgPlacebo
Change From Baseline in Apnoea-hypopnoea Index (AHI)-12.22 ± 23.34-6.08 ± 25.90
Statistical analysis
  • Liraglutide 3.0 mg vs Placebo · ANCOVA · p = 0.015 · Estimated treatment difference: -6.10 · 95% CI -11.0 to -1.19ANCOVA model was used with treatment, country and sex as fixed factors, and the baseline value of AHI, baseline BMI and baseline age as covariates.
SecondaryChange From Baseline in Body Weight (kg)

Observed mean change from baseline in fasting body weight (kg) after 32 weeks of treatment.

Time frame:
Week 0, week 32
Reported as:
Mean · kg
Change From Baseline in Body Weight (kg)
kgLiraglutide 3.0 mgPlacebo
Change From Baseline in Body Weight (kg)-6.73 ± 6.59-1.87 ± 5.44
SecondaryChange From Baseline in Fasting Plasma Glucose

Observed mean change from baseline in fasting plasma glucose (mmol/L) after 32 weeks of treatment.

Time frame:
Week 0, week 32
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Plasma Glucose
mmol/LLiraglutide 3.0 mgPlacebo
Change From Baseline in Fasting Plasma Glucose-0.15 ± 0.690.17 ± 0.96
SecondaryChange From Baseline in Glycosylated Haemoglobin (HbA1c) (%)

Observed mean change from baseline in glycosylated haemoglobin (HbA1c) (%) after 32 weeks of treatment.

Time frame:
Week 0, week 32
Reported as:
Mean · percentage of glycosylated haemoglobin
Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%)
percentage of glycosylated haemoglobinLiraglutide 3.0 mgPlacebo
Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%)-0.36 ± 0.30-0.17 ± 0.29

Adverse events

Collected over Events that either occur before randomisation and increase in severity during the treatment period or have an onset date on or after the first day of randomised treatment and no later than 14 days after the last day of randomised treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Liraglutide 3.0 mg—6/176 (3.4%)117/176 (66.5%)
Placebo—6/179 (3.4%)84/179 (46.9%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventLiraglutide 3.0 mgPlacebo
Angina pectorisCardiac disorders2/1760/179
Sinus arrestCardiac disorders1/1760/179
CholelithiasisHepatobiliary disorders1/1760/179
PneumoniaInfections and infestations1/1760/179
Procedural painInjury, poisoning and procedural complications1/1760/179
Spinal fractureInjury, poisoning and procedural complications1/1760/179
DehydrationMetabolism and nutrition disorders1/1760/179
AnxietyPsychiatric disorders1/1760/179
Depression suicidalPsychiatric disorders1/1760/179
Oropharyngeal swellingRespiratory, thoracic and mediastinal disorders1/1760/179
Most frequent other events
Showing 10 of 13
Most frequent other events
EventLiraglutide 3.0 mgPlacebo
NauseaGastrointestinal disorders47/17612/179
DiarrhoeaGastrointestinal disorders29/17614/179
HeadacheNervous system disorders25/17620/179
ConstipationGastrointestinal disorders21/1766/179
Upper respiratory tract infectionInfections and infestations18/17619/179
NasopharyngitisInfections and infestations15/17618/179
DyspepsiaGastrointestinal disorders15/1762/179
VomitingGastrointestinal disorders13/1765/179
Injection site haematomaGeneral disorders7/17613/179
Gastrooesophageal reflux diseaseGastrointestinal disorders10/1760/179

Baseline characteristics

Age, Continuous
Age, Continuous(years)Liraglutide 3.0 mgPlaceboTotal
Mean48.6 ± 9.948.4 ± 9.548.5 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Liraglutide 3.0 mgPlaceboTotal
Female5150101
Male129129258
Body weight
Body weight(kg)Liraglutide 3.0 mgPlaceboTotal
Mean116.5 ± 23.0118.7 ± 25.4117.6 ± 24.2
Body mass index (BMI)
Body mass index (BMI)(kg/m^2)Liraglutide 3.0 mgPlaceboTotal
Mean38.9 ± 6.439.4 ± 7.439.1 ± 6.9
Apnoea-hypopnoea index (AHI)
Apnoea-hypopnoea index (AHI)(events/hour)Liraglutide 3.0 mgPlaceboTotal
Mean49.0 ± 27.549.3 ± 27.549.2 ± 27.4
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mmol/L)Liraglutide 3.0 mgPlaceboTotal
Mean5.4 ± 0.65.4 ± 0.95.4 ± 0.8
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(Percent (%) glycosylated haemoglobin)Liraglutide 3.0 mgPlaceboTotal
Mean5.7 ± 0.45.6 ± 0.45.7 ± 0.4
09

Study locations

42 sites
  • Novo Nordisk Investigational Site
    Glendale, California 91206, United States
  • Novo Nordisk Investigational Site
    Oceanside, California 92054, United States
  • Novo Nordisk Investigational Site
    Orange, California 92868, United States
  • Novo Nordisk Investigational Site
    Redwood City, California 94063, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92103-5801, United States
  • Novo Nordisk Investigational Site
    Santa Monica, California 90404, United States
  • Novo Nordisk Investigational Site
    Brandon, Florida 33511, United States
  • Novo Nordisk Investigational Site
    Hollywood, Florida 33024, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33155, United States
  • Novo Nordisk Investigational Site
    Saint Petersburg, Florida 33707, United States
  • Novo Nordisk Investigational Site
    South Miami, Florida 33143, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33603, United States
  • Novo Nordisk Investigational Site
    West Palm Beach, Florida 33409, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30342, United States
  • Novo Nordisk Investigational Site
    Macon, Georgia 31201, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60634, United States
  • Novo Nordisk Investigational Site
    Vernon Hills, Illinois 60061, United States
  • Novo Nordisk Investigational Site
    Overland Park, Kansas 66212, United States
  • Novo Nordisk Investigational Site
    Crestview Hills, Kentucky 41017-3464, United States
  • Novo Nordisk Investigational Site
    Louisville, Kentucky 40218, United States
  • Novo Nordisk Investigational Site
    Chevy Chase, Maryland 20815-6905, United States
  • Novo Nordisk Investigational Site
    North Dartmouth, Massachusetts 02747, United States
  • Novo Nordisk Investigational Site
    Portage, Michigan 49024-4889, United States
  • Novo Nordisk Investigational Site
    Chesterfield, Missouri 63017, United States
  • Novo Nordisk Investigational Site
    New York, New York 10019, United States
  • Novo Nordisk Investigational Site
    New York, New York 10065, United States
  • Novo Nordisk Investigational Site
    Wilmington, North Carolina 28401, United States
  • Novo Nordisk Investigational Site
    Dublin, Ohio 43017-3521, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19104-3317, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19118, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • Novo Nordisk Investigational Site
    Warwick, Rhode Island 02886, United States
  • Novo Nordisk Investigational Site
    Columbia, South Carolina 29201-2951, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75231, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75234, United States
  • Novo Nordisk Investigational Site
    Fort Worth, Texas 76135, United States
  • Novo Nordisk Investigational Site
    Vienna, Virginia 22182, United States
  • Novo Nordisk Investigational Site
    Burlington, Ontario L7R 1E2, Canada
  • Novo Nordisk Investigational Site
    Hamilton, Ontario L8L 5G8, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M4P 1P2, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M5M 1C7, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M5M1C7, Canada
10

References and documents

Publications

  • O'Neil PM, Garvey WT, Gonzalez-Campoy JM, Mora P, Ortiz RV, Guerrero G, Claudius B, Pi-Sunyer X; Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS. Endocr Pract. 2016 Nov;22(11):1277-1287. doi: 10.4158/EP151181.OR. Epub 2016 Aug 2. PubMed 27482610 ↗
  • Bays H, Pi-Sunyer X, Hemmingsson JU, Claudius B, Jensen CB, Van Gaal L. Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects. Curr Med Res Opin. 2017 Feb;33(2):225-229. doi: 10.1080/03007995.2016.1251892. Epub 2016 Nov 6. PubMed 27817208 ↗
  • Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, Claudius B, Jensen CB, Mignot E. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016 Aug;40(8):1310-9. doi: 10.1038/ijo.2016.52. Epub 2016 Mar 23. PubMed 27005405 ↗
  • Steinberg WM, Rosenstock J, Wadden TA, Donsmark M, Jensen CB, DeVries JH. Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. Diabetes Care. 2017 Jul;40(7):839-848. doi: 10.2337/dc16-2684. Epub 2017 May 4. Erratum In: Diabetes Care. 2018 Jul;41(7):1538. doi: 10.2337/dc18-er07. PubMed 28473337 ↗
  • O'Neil PM, Aroda VR, Astrup A, Kushner R, Lau DCW, Wadden TA, Brett J, Cancino AP, Wilding JPH; Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017 Nov;19(11):1529-1536. doi: 10.1111/dom.12963. Epub 2017 Jul 21. PubMed 28386912 ↗
  • Davies MJ, Aronne LJ, Caterson ID, Thomsen AB, Jacobsen PB, Marso SP; Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab. 2018 Mar;20(3):734-739. doi: 10.1111/dom.13125. Epub 2017 Nov 1. PubMed 28950422 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Jun 2013, 11 months.

Results were first posted in Feb 2015, 1 year 8 months after primary completion. A results delay was requested in Jun 2014.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 11 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2012
First posted
Mar 19, 2012
StartActual
Jun 7, 2012
Primary completionActual
Jun 1, 2013
CompletionActual
Jun 17, 2013
Results delay requested
Jun 10, 2014
Results first posted
Feb 9, 2015
Last update
Nov 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01557166
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 19, 2012
Start date
Jun 7, 2012
Primary completion
Jun 1, 2013
Completion
Jun 17, 2013
Results posted
Feb 9, 2015
Last update
Nov 1, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion